KA-3003

KA-3003: sourced facts only. name: "KA-3003 exhibits high affinity for PSMA and relatively lower affinity for CD28 and CD137." [DOI:10.1158/1538-7445.am2024-2378]; target: "KA-3003 exhibits high affinity for PSMA and relatively lower affinity for CD28 and CD137." [DOI:10.1158/1538-7445.am2024-2378]; target: "KA-3003 exhibits high affinity for PSMA and relatively lower affinity for CD28 and CD137." [DOI:10.1158/1538-7445.am2024-2378]; target: "KA-3003 exhibits high affinity for PSMA and relatively lower affinity for CD28 and CD137." [DOI:10.1158/1538-7445.am2024-2378]; developer: "1Kyinno Biotechnology Co., Ltd, Beijing, China." [DOI:10.1158/1538-7445.am2024-2378]; modality: "Here, we developed a tri-specific antibody, KA-3003, targeting PSMA, CD28, and 4-1BB, with the goal of enhancing T cell activation in the tumor microenvironment." [DOI:10.1158/1538-7445.am2024-2378]; stage: "In PBMC humanized immunodeficient mouse tumor models, KA-3003 effectively suppresses the growth of 22Rv1 tumors with or without a PD1 antagonist antibody." [DOI:10.1158/1538-7445.am2024-2378]